RAFAEL FERREIRA COELHO

(Fonte: Lattes)
Índice h a partir de 2011
23
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2021 ×

Resultados de Busca

Agora exibindo 1 - 10 de 25
  • article 2 Citação(ões) na Scopus
    Recommendations on robotic-assisted radical prostatectomy: a Brazilian experts' consensus
    (2021) FARIA, Eliney Ferreira; MACIEL, Carlos Vaz Melo; BERGER, Andre; MITRE, Anuar; DAUSTER, Breno; FREITAS JR., Celso Heitor; FRAGA, Clovis; CHADE, Daher; DALL'OGLIO, Marcos; CARVALHO, Francisco; CAMPOS, Franz; CARVALHAL, Gustavo Franco; LEMOS, Gustavo Caserta; GUIMARAES, Gustavo; ZAMPOLLI, Hamilton; ALVES, Joao Ricardo; MANZANO, Joao Padua; FORTES, Marco Antonio; ROCHA, Marcos Flavio Holanda; RUBINSTEIN, Mauricio; LUZ, Murilo; ROMANELLI, Pedro; COELHO, Rafael; ROCHA, Raphael; MACHADO, Roberto Dias; REIS, Rodolfo Borges dos; ZEQUI, Stenio; GUIDA, Romulo; MUGLIA, Valdair; TOBIAS-MACHADO, Marcos
    Radical prostatectomy is a commonly adopted treatment for localized/locally advanced prostate cancer in men with a life expectancy of ten years or more. Robotic-assisted radical prostatectomy (RARP) is comparable to open radical prostatectomy on cancer control and complication rates; however, new evidence suggests that RARP may have better functional outcomes, especially with respect to urinary incontinence and erectile dysfunction. Some of the surgical steps of RARP are not adequately described in published literature and, as such, may have an impact on the final outcomes of the procedure. We organized a Brazilian experts' panel to evaluate best practices in RARP. The confection of the recommendations broadly involved: selection of the experts; establishment of working groups; systematic review of the literature and elaboration of a questionnaire; and construction of the final text with the approval of all participants. The participants reviewed the publications in English from December 2019 to February 2020. A one-round Delphi technique was employed in 188 questions. Five reviewers worked on the final recommendations using consensual and non-consensual questions. We found 59.9% of questions with greater than 70% agreement that were considered consensual. Non-consensual questions were reported according to the responses. The recommendations were based on evidence-based literature and individual perceptions adapted to the Brazilian reality, although some issues remain controversial. We believe that these recommendations may help urologists involved in RARP and hope that future discussions on this surgical procedure may evolve over the ensuing years.
  • article 5 Citação(ões) na Scopus
    Noninvasive intracranial pressure real-time waveform analysis monitor during prostatectomy robotic surgery and Trendelenburg position: case report
    (2021) SABA, Gabriela Tognini; QUINTÃO, Vinicius Caldeira; ZEFERINO, Suely Pereira; SIMÕES, Claudia Marquez; COELHO, Rafael Ferreira; FAZOLI, Arnaldo; NAHAS, William; VILELA, Gustavo Henrique Frigieri; CARMONA, Maria José Carvalho
    Abstract Both robotic surgery and head-down tilt increase intracranial pressure by impairing venous blood outflow. Prostatectomy is commonly performed in elderly patients, who are more likely to develop postoperative cognitive disorders. Therefore, increased intracranial pressure could play an essential role in cognitive decline after surgery. We describe a case of a 69-year-old male who underwent a robotic prostatectomy. Noninvasive Brain4care™ intraoperative monitoring showed normal intracranial compliance during anesthesia induction, but it rapidly decreased after head-down tilt despite normal vital signs, low lung pressure, and adequate anesthesia depth. We conclude that there is a need for intraoperative intracranial compliance monitoring since there are major changes in cerebral compliance during surgery, which could potentially allow early identification and treatment of impaired cerebral complacency.
  • article 2 Citação(ões) na Scopus
    Robot-assisted simple prostatectomy: the evolution of a surgical technique
    (2021) RODRIGUES, Gilberto J.; SAWCZYN, Guilherme V.; GUGLIELMETTI, Giuliano B.; FAZOLI, Arnaldo J. C.; TANURE, Luis H. R.; NAHAS, William C.; COELHO, Rafael F.
  • conferenceObject
    Randomized controlled trial comparing holmium laser en-bloc resection with monopolar transurethral resection in patients with large bladder tumors
    (2021) ISCAIFE, A.; RIBEIRO FILHO, L. A.; PEREIRA, M. W. Aparecido; GALLUCCI, F. Pescarmona; CHADE, D.; CARDILI, L.; COELHO, R. F.; SARKIS, A. Sadeki; SROUGI, M.; NAHAS, W. C.
  • article 0 Citação(ões) na Scopus
  • article 4 Citação(ões) na Scopus
    MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma
    (2021) CARVALHO, Paulo Afonso de; BONATELLI, Murilo; CORDEIRO, Mauricio Dener; COELHO, Rafael Ferreira; REIS, Sabrina; SROUGI, Miguel; NAHAS, Willian Carlos; PINHEIRO, Celine; LEITE, Katia Ramos Moreira
    Clear cell renal cell carcinoma (ccRCC) has been considered a metabolic disease, with loss of von Hippel-Lindau (VHL) gene and consequent overexpression of hypoxia-inducible factor 1 alpha (HIF-1a), which is central for tumor development and progression. Among other effects, HIF-1a is involved in the metabolic reprogramming of cancer cells towards the Warburg effect involved in tumor cell proliferation, migration and survival. In this context, several proteins are expressed by cancer cells, including glucose and lactate transporters as well as different pH regulators. Among them, monocarboxylate transporters (MCTs) can be highlighted. Our aim is to comprehensively analyze the immunoexpression of MCT1, MCT2, MCT4, CD147, CD44, HIF-1 alpha, GLUT1 and CAIX in ccRCC surgical specimens correlating with classical prognostic factors and survival of patients with long follow-up. Surgical specimens from 207 patients with ccRCC who underwent radical or partial nephrectomy were used to build a tissue microarray. Immunostaining was categorized into absent/weak or moderate/strong and related to all classic ccRCC prognostic parameters. Kaplan-Meier curves were generated to assess overall and cancer-specific survival, and multivariate analysis was performed to identify independent prognostic factors of survival. Multivariate analysis showed that MCT1 together with tumor size and TNM staging, were independently related to cancerspecific survival. MCT1, CD147, CD44 and GLUT1 expression were significantly associated with poor prognostic factors. We show that MCT1 is an independent prognostic factor for cancer-specific survival in ccRCC justifying the use of new target therapies already being tested in clinical trials.
  • conferenceObject
    A PROSPECTIVE ANALYSIS OF TESTOSTERONE (T) RECOVERY PROFILES AFTER NEOADJUVANT MAXIMAL ANDROGEN BLOCKADE IN HIGH-RISK LOCALIZED PROSTATE CANCER
    (2021) PEDRENHO NETO, Rubens; NASCIMENTO, Bruno C. G.; BASTOS, Diogo Assed; BESSA JUNIOR, Jose de; ILARIO, Eder Nisi; MURTA, Claudio Bovolenta; CORDEIRO, Mauricio Dener; COELHO, Rafael Ferreira; MULHALL, John P.; SROUGI, Miguel; NAHAS, William Carlos
  • article 13 Citação(ões) na Scopus
    Opioids and premature biochemical recurrence of prostate cancer: a randomised prospective clinical trial
    (2021) RANGEL, Felipe P.; JR, Jose O. C. Auler; CARMONA, Maria J. C.; CORDEIRO, Mauricio D.; NAHAS, William C.; COELHO, Rafael F.; SIMOES, Claudia M.
    Background: Prostate cancer is one of the most prevalent neoplasms in male patients, and surgery is the main treatment. Opioids can have immune modulating effects, but their relation to cancer recurrence is unclear. We evaluated whether opioids used during prostatectomy can affect biochemical recurrence-free survival. Methods: We randomised 146 patients with prostate cancer scheduled for prostatectomy into opioid-free anaesthesia or opioid-based anaesthesia groups. Baseline characteristics, perioperative data, and level of prostate-specific antigen every 6 months for 2 yr after surgery were recorded. Prostate-specific antigen >0.2 ng ml(-1) was considered biochemical recurrence. A survival analysis compared time with biochemical recurrence between the groups, and a Cox regression was modelled to evaluate which variables affect biochemical recurrence-free survival. Results: We observed 31 biochemical recurrence events: 17 in the opioid-free anaesthesia group and 14 in the opioidbased anaesthesia group. Biochemical recurrence-free survival was not statistically different between groups (P=0.54). Cox regression revealed that biochemical recurrence-free survival was shorter in cases of obesity (hazard ratio [HR] 1.63, confidence interval [CI] 0.16-3.10; p=0.03), high D'Amico risk (HR 1.58, CI 0.35-2.81; P=0.012), laparoscopic surgery (HR 1.6, CI 0.38-2.84; P=0.01), stage 3 tumour pathology (HR 1.60, CI 0.20-299) and N1 status (HR 1.34, CI 0.28-2.41), and positive surgical margins (HR 1.37, CI 0.50-2.24; P=0.002). The anaesthesia technique did not affect time to biochemical recurrence (HR -1.03, CI -2.65-0.49; P=0.18). Conclusions: Intraoperative opioid use did not modify biochemical recurrence rates and biochemical recurrence-free survival in patients with intermediate and high D?Amico risk prostate cancer undergoing radical prostatectomy. Clinical trial registration: NCT03212456.
  • conferenceObject
    LAPAROSCOPIC AND ROBOT-ASSISTED LEVEL II AND III INFERIOR VENA CAVA TUMOR THROMBECTOMY
    (2021) SAWCZYN, Guilherme; CORDEIRO, Mauricio; GUGLIELMETTI, Giuliano; FAZOLI, Arnaldo; RODRIGUES, Gilberto; VILLAMIL, Wenceslao; MARCHINENA, Patricio; JURADO, Alberto; ROMEO, Agustin; ROMANELLI, Pedro; ARANTES, Paulo; NISTER, Matheus; TANURE, Luis; VICENTINI, Fabio; ALVES, Joao; DOURADO, Aurus; NAHAS, William; COELHO, Rafael
  • article 3 Citação(ões) na Scopus
    Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor
    (2021) QUEIROZ, Marcello Moro; SOUZA, Zenaide Silva de; GONGORA, Aline Bobato Lara; BARBOSA, Felipe de Galiza; BUCHPIGUEL, Carlos Alberto; CASTRO, Marilia Germanos de; MACEDO, Mariana Petaccia de; COELHO, Rafael Ferreira; SOKO, Ethan Samuel; CAMARGO, Anamaria Aranha; BASTOS, Diogo Assed
    Immunotherapy has recently been incorporated into the treatment guidelines for metastatic urothelial carcinoma. Nevertheless, the role of prognostic and predictive biomarkers in this setting is not completely defined. To date, PD-L1 expression and a high tumour mutational burden (TMB) seem to predict better responses to immune checkpoint inhibitors, but patients without these biomarkers may still respond to immunotherapy. There are some caveats regarding these biomarkers, such as lack of standardisation of techniques, tumour heterogeneity and other factors influencing the tumour microenvironment. Genomic signatures are other promising emerging strategies. We hereby discuss the management of a 70-year-old man with a metastatic recurrence of urothelial carcinoma within 1 year after neoadjuvant chemotherapy and radical cystectomy. Tumour next-generation sequencing showed a high TMB and a CD274 (PD-L1) amplification. The patient was treated with pembrolizumab and achieved a complete response.